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Gene expression profiles of mucosal fibroblasts from strictured
and nonstrictured areas of patients with Crohn's disease
Abstract
Background: A frequent complication of Crohn's disease (CD) is the formation of strictures and
stenoses. Strictures are characterized by a fibrosis of the bowel wall, induced by abnormal wound
healing. Functional changes of colonic lamina propria fibroblasts (CLPF) reflected by increased
proliferation and collagen synthesis, increased contractility or reduced migratory potential, indicate a
change of the phenotype. We aimed to investigate differences in gene expression profiles between CLPF
isolated from normal, inflamed and strictured areas of CD patients. Methods: We applied two methods
of gene expression analysis, subtractive hybridisation and Affimetrix(R) microarrays to find differences
in mRNA expression patterns. Findings were verified by dot blot analysis. Results: Using subtractive
screening and dot blot analysis 74 clones could be confirmed to be differentially expressed in CD CLPF
from nonstrictured areas compared to control CLPF. Fibronectin (transcript variant 1, NM_002026)
could be confirmed as being upregulated in CD with a ratio of 143. Collagen (type I, NM_000089) was
upregulated in CD with a ratio of 17.41 clones could be confirmed as differentially expressed in CD
CLPF derived from strictures compared to control CLPF. Five clones were identified as chitinase 3-like
1 (cartilage glycoprotein-39) and confirmed with dot blot with a ratio of 2.1.In an independent approach,
microarray analysis showed upregulation of chitinase 3-like 1 (signal log ratio 1.9) in CD CLPF from
strictures compared to control CLPF thus confirming subtractive hybridization.Conclusions: In the light
of the current literature a number of interesting candidates resulted from the multiplicity of identified
genes. In regard to the functional changes of CLPF during stenosis and other dysfunctions some proteins
might represent a therapeutic target.
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α-SMA, alpha smooth muscle cell actin; bFGF, basic fibroblast growth factor; CD, 
Crohn’s disease; CLPF, colonic lamina propria fibroblasts; EDTA, 
ethylenediaminetetraacetic acid; EGF, epidermal growth factor; IBD, inflammatory 
bowel disease; IGF-1, insulin-like growth factor 1; NF-κB, nuclear factor-κB; PBS, 
phosphate-buffered saline; PDGF, platelet-derived growth factor; SSCP, single strand 
conformation polymorphism; TGF-β1, transforming growth factor β1; TNF, tumor 
necrosis factor; V, vimetin 
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Introduction 
A frequent complication of Crohn’s disease (CD) is the formation of strictures and 
stenoses (1-5). More than one third of all CD patients have a stenosing disease 
phenotype (2) being one of the main reasons for surgery. Formation of strictures is 
characterized by a fibrosis of the bowel wall, induced by a misbalanced wound healing 
(6). Stricturing disease usually occurs only if chronic or relapsing inflammation is 
present which is accompanied by severe tissue destruction (6). This is followed by the 
proliferation of mesenchymal cells and by an increased synthesis and deposition of 
collagen fibrils in all layers of the intestinal wall. However, the cellular mechanisms of 
fibrosis in the intestinum have not been investigated to the same extent as in other 
organs, such as the liver, the skin, or the vascular system (2). 
Fibroblasts isolated from the lamina propria of CD strictures produce more collagen 
type III compared to fibroblasts from non-strictured and normal mucosa. Powell and 
colleagues suspected activated α-smooth muscle cell actin positive myofibroblasts as 
being responsible for the increased formation of extracellular matrix proteins (7, 8). 
Hitherto it is not clear from which mesenchymal cell type those myofibroblasts origin. 
Among the factors that induce the activation of mesenchymal cells into a fibrogenic 
phenotype are growth factors such as insulin-like growth factor 1 (IGF-1), basic 
fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and transforming 
growth factor-β1 (TGF-β1) (9-11). Regan and coworkers showed an increased 
contractility of fibroblasts from strictures in CD patients (12).  
In addition to their role in fibrosis and stricture formation intestinal fibroblasts play an 
important role during inflammation in CD patients secreting cytokines, chemokines, 
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growth factors and matrix degrading enzymes (13-18). One of the most important 
transcription factorsinvolved in the regulation of those genes is nuclear factor-κB (NF-
κB). In inflamed mucosa activated NF-κB is mainly found in macrophages and epithelial 
cells (19). A further cell population containing activated NF-κB was found in strictured 
areas of CD patients, likely being fibroblasts or myofibroblasts (19).  
The migration of fibroblasts into injured tissue is an important pre-requisite for the 
restoration of a defect. Fibroblasts from the lamina propria of the colon (CLPF) simulate 
their own migration autocrine and paracrine by the secretion of fibronectin (20). PDGF-
AB, TGF-β1, IGF-1 and epidermal growth factor (EGF) further increase this migratory 
potential (21). CLPF of patients with CD show a markedly reduced migration in vitro 
compared to CLPF from normal mucosa (22). The underlying molecular mechanisms for 
this so far are not well understood. Functional changes of fibroblasts/myofibroblasts 
reflected by increased proliferation and collagen synthesis, increased contractility or 
reduced migratory potential indicate a change of the phenotype. Whether these 
changes are mediated by a disease specific genetic background or the composition of 
the inflammatory milieu is unclear.  
In liver fibrosis the molecular mechanisms have been studied in more detail. To 
characterize the gene expression profile associated with the activation of quiescent 
hepatic stellate cells to fibrogenic myofibroblasts, Liu and coworkers performed a cDNA 
microarray analysis in activated stellate cells of the mouse (23). They found a number 
of new genes to be regulated. Among those found to be upregulated were annexin 6, 
caveolin 1, caveolin 2, chaperon containing t-complex polypeptide 1, cyclin B1, 
macrophage migration inhibitory factor, N-cadherin, replication factor C and uridine 
diphosphoglucose hydrogenase (23).  
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As we had demonstrated that there are a number of functional changes in colonic 
fibroblasts derived from CD patients and even more pronounced in cells derived from 
strictures we aimed to investigate differences in gene expression profiles between CLPF 
isolated from normal, inflamed and strictured areas of CD patients. We applied two 
methods of gene expression analysis, subtractive hybridisation and Affimetrix® 
microarrays to find differences in mRNA expression patterns. mRNA expression patterns 
of a) CLPF from non-strictured areas of CD patients with control CLPF b) CLPF from 
strictured areas with control CLPF and c) CLPF from non-strictured areas with strictures 
of the same patient were compared. Findings were verified by dot blot analysis. 
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Material and methods 
Patients 
Primary human CLPF cultures were obtained from endoscopic biopsies or surgical 
specimens taken from healthy areas of the mucosa of patients undergoing surgery for 
colorectal carcinoma or from the mucosa of patients with CD. The degree of 
inflammation was graded microscopically by a blinded pathologist by determination of 
the inflammatory infiltrate of neutrophils, eosinophils, and lymphocytes: no 
inflammation, low degree of inflammation and severe inflammation. The treatment of 
the patients is given in table 1. Of a total number of 30 subjects, 12 were male and 18 
were female. Patients were between 17 and 74 (mean 41.8 ± 17.3) years of age and 
treated with budesonide, 5-ASA, azathioprine and systemic steroids. The study was 
approved by the Ethics Committee of the University of Regensburg.  
 
Isolation and culture of human CLPF 
Human CLPF were isolated and cultured as described earlier (21). The mucosa from 
surgical specimens was cut into 1mm pieces while the biopsies were used directly for 
the isolation of CLPF. Epithelial cells were removed in Hank’s Balanced Salt Solution 
without Ca2+ and Mg2+ (PAA, Cölbe, Germany) with 2 mM EDTA (SIGMA, Deisenhofen, 
Germany). The remaining tissue was digested for 30 minutes at 37°C with 1 mg/ml 
collagenase 1 (SIGMA), 0.3 mg/ml DNase I (Boehringer, Mannheim, Germany) and 2 
mg/ml hyaluronidase (SIGMA) in PBS (Gibco, Karlsruhe, Germany). The isolated cells 
were cultured in 25 cm2 culture flasks (Costar, Bodenheim, Germany) with DMEM 
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containing 10% fetal calf serum, penicillin (100 IE/ml), streptomycin (100 µg/ml), 
ciprofloxacin (8 µg/ml), gentamycin (50 µg/ml) and amphotericin B (1 µg/ml). Non-
adherent cells were removed. The remaining cells were characterized by 
immunocytochemistry and used between passage 3 and 8. 
 
Isolation of mRNA from CLPF 
mRNA was isolated by oligo(dT) cellulose (FastTrack® 2.0 kit, Invitrogen, Carlsbad, CA, 
USA) from CLPF according to the manufacturer’s protocol. Integrity of the mRNA was 
verified by Gene Checker™ kit (Invitrogen, Carlsbad, CA, USA). mRNA was reverse 
transcribed with the Reverse Transcription System (Promega, Mannheim, Germany). 
 
Subtractive screening 
Subtractive screening of the cDNA populations was performed with the PCR-Select 
cDNA subtraction kit (Clontech, Palo Alto, CA, USA) as recently described for intestinal 
macrophages (24). cDNA from CLPF supposed to be tested was termed “tester 
population”. cDNA from CLPF for comparison was named “driver population”. Only 
molecules from the desired differentially expressed sequences from the tester 
population were amplified exponentially. A secondary PCR amplification was performed 
using nested primers to further reduce any background PCR products and enrich for 
differentially expressed sequences. 
Polyacrylamide gel electrophoresis and single strand conformation polymorphism 
(SSCP) gel electrophoresis were performed with the subtracted cDNA. Products were 
cloned with TOPO™-TA Cloning Kit (Invitrogen, Carlsbad, CA, USA), sequenced and a 
similarity search was performed. The World Wide Web address to access the nucleic 
Lang et al        Gene expression profiles of mucosal fibroblasts from CD strictures  
 
8
acid sequences is http://www.ncbi.nlm.nih.gov/index.shtml.04082004. The result of the 
BLAST records was given together with a score (arbitrary units), considering length of 
the alignment, mismatches and gaps. A higher score, therefore, means a greater 
degree of similarity. In this work only hits with an arbitrary score > 700 bits were 
selected for further analysis.  
 
Dot blot analysis 
Several cDNA products obtained by subtractive screening were verified by dot blot 
analyses with cDNA not used for subtractive screening as recently described (24). Each 
of the cDNA products were blotted on two membranes (GB 003, Schleicher & Schuell, 
Dassel, Germany) together with cDNA from five different house keeping genes and UV 
crosslinked (1200 μJ x 100, UV-Stratalinker 1800, Stratagene). cDNA from driver CLPF 
and cDNA from tester CLPF were labeled with 32-P dATP (Amersham Biosciences, 
Freiburg, Germany) and purified with Sephadex G-50 columns (NICK columns, 
Amersham Biosciences, Freiburg, Germany) and denatured at 95°C for 5 minutes. 
1x105 – 1x106 cpm/ml were hybridized for 16 hours at 42°C with one membrane each. 
Membranes were washed in 2 x SSC with 0.1% SDS at room temperature for 5 
minutes, followed by 0.5 x SSC with 0.1% SDS and 0.1 x SSC with 0.1% SDS at room 
temperature for 20 minutes respectively. Finally membranes were washed with 0.1 x 
SSC with 1% SDS at 65°C for 30 minutes. Bound radioactivities were determined with a 
storage phosphor screen (Amersham Biosciences, Freiburg, Germany).  
Values were corrected (subtraction of background) and normalized to the house 
keeping genes. The ratio of normalized signals of the 2 membranes was calculated as 
Lang et al        Gene expression profiles of mucosal fibroblasts from CD strictures  
 
9
“tester versus driver”. Dot blot experiments were performed twice and differences were 
considered differentially expressed at a mean ratio > 2.0. 
 
Affymetrix analysis 
Affymetrix GeneChip® analysis was performed with help of the Kompetenzzentrum für 
fluoreszente Bioanatytik (KFB) in Regensburg (Germany). mRNA was isolated from 
CLPF cultures as indicated above by using polyT magnetic beads (Dynal, Oslo, Norway). 
In each case RNA from 3 patients was pooled to avoid individual differences responsible 
for variation.  
Double-stranded cDNA was synthesized by a Superscript II kit (Life Technologies, 
Karlsruhe, Germany) using T7-oligo(dT) as primer. Biotin-labeled cRNA was prepared 
by in vitro transcription reaction using an Enzo BioArray HighYield RNA Transcript 
Labeling Kit (Affymetrix, P/N 900182) based on the manufacturer’s protocol. The Biotin-
labeled cRNA was purified, fragmented and after addition of Control Oligonucleotide B2 
(3nM) and 20X Eukaryotic Hybridization Controls (bioB, bioC, bioD, cre) hybridized to 
Affymetrix HG-U133A GeneChips (Affymetrix, Santa Clara, CA, USA), scanned on the 
Affymetrix array scanner and data analysis performed using the Affymetrix statistical 
data analysis software, Affymetrix Microarray Suite (version 5.0). 
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Results 
 
General approach of subtractive hybridization 
To identify differences in gene expressions between CLPF from control patients, non 
strictured areas of CD patients and strictured areas, a subtractive hybridisation 
screening was performed. Three different hybridisation approaches were performed: 
1. CD CLPF cDNA was subtracted from that of control CLPF. 
2. Stricture associated CD CLPF cDNA was subtracted from control CLPF and  
3. CD CLPF were subtracted from stricture CLPF.  
For the first two approaches, mRNAs derived from patient CLPFs were pooled. Pooling 
was performed to avoid subtraction of genes that are not related to the disease specific 
differentiation of fibroblasts, but reflect genetic specificities of specific patients. Such 
patients specific genes for example would be HLA-genes or genes regulated by sex 
hormones. The third approach was performed with unpooled mRNA from one patient. 
CLPF from strictured and non strictured mucosal areas of this patient were compared 
for disease stage specific gene expression differences.  
 
Subtraction of CD CLPF from non strictured areas with control CLPF  
Four different CD mRNA’s were pooled. As driver, a mRNA pool of four patients without 
IBD was used. After subtractive hybridisation, 23 bands were obtained in a 
polyacrylamid gel and cut out. The bands were cloned into PCR2.1–TOPO vector and 
transformed in E. coli TOP10. A blue/white screening was performed. 282 clones of the 
differential expressed cDNAs were generated and sequenced. The obtained nucleic acid 
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sequences were compared with the sequence of known clones with the nucleotide 
sequence bank of the Entrez Browser of the National Institute of Health (NIH, 
Bethesda, Maryland USA, address: www.ncbi.nlm.nih.gov) clones with a comparison 
score of less than 700 bits were ignored resulting in 198 clones of which the first ten 
are listed in the table 2. The full table is accessable as additional material. 
These clones represent genes, which are expressed in CD CLPF from non strictured 
areas but not or to a lesser extend in CLPF from control mucosa without inflammation. 
5 clones were identified as fibronectin (transcript variant 1, mRNA) with the NCBI 
accession number NM_002026 (table 2). To verify the specificity of the mentioned 
genes, dot blots were performed. For the dot blots, the insert of the different plasmids 
were amplified by PCR and blotted on two nylon membranes. As a positive control, 5 
different 500 – 1000 bp PCR products of housekeeping genes were also blotted: a PCR 
product from the 3’ and the 5’ region of actin, two different regions from clathrin and a 
sequence of GAPDH. A mRNA pool of three different CD patients, which were different 
from the ones that were used for subtractive hybridization and of three different control 
patients, not identical to the ones used for subtractive hybridisation, were used for the 
cDNA synthesis. In table 2 the average quotients of this experiment are given. Genes 
with a value of at least 2.0 were regarded as differentially expressed. The complete 
table is accessable as additional material. 
Out of the 198 further investigated clones, 74 could be confirmed to be differentially 
expressed in CD CLPF. The amount of true positive clones is comparable to what was 
expected from the literature on subtractive hybridization. Fibronectin (transcript variant 
1, mRNA) could be confirmed as being upregulated in CD with a ratio of 143 (mean of 
two experiments, tester versus driver, table 2, figure 1A).  
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Using the technique of subtractive screening another clone was identified as collagen 
(type I, alpha 2, COL1A2, mRNA) with the NCBI accession number NM_000089 (ratio 
CD vs. control 17, table 2 additional material).  
 
Subtraction of CD CLPF derived from strictures and control CLPF. 
This approach aimed at genes that were expressed in CD CLPF from strictures and not 
in CLPF from control patients. A subtraction “stricture minus control” was performed. 
After the nested PCR 14 distinct bands could be isolated from the gel. The PCR 
products were cloned and plasmids generated. After blue/white selection finally 282 
positive clones could be obtained and were sequenced. Table 3 gives a list of the most 
abundant 10 clones. The complete list of 282 clones is accessable as additional 
material. The clones represent genes which are expressed in CD CLPF from strictured 
areas, however not in CLPF from patients without IBD. Specificity of the most abundant 
clones was revised with dot blot analysis. A mRNA pool from three different strictured 
patients and three different control patients, not identical to the ones that were used 
for subtractive hybridisation, were hybridized. 
Three different dot blot experiments were performed. Table 3 gives the average 
quotient of “intensity stricture versus intensity control” from three experiments (10 are 
shown in the manuscript, the whole list is accessable as additional material). Out of the 
investigated clones, 41 could be confirmed as differentially expressed. While fibronectin 
(transcript variant 1, mRNA) was not identified in the subtraction it was nevertheless 
tested additionally on the dot blot. Again, fibronectin (transcript variant 1, mRNA) could 
be confirmed as being upregulated in CD CLPF from strictured areas with a ratio of 63 
(mean of two experiments, tester versus driver, figure 1B). 5 clones were identified by 
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subtraction as chitinase 3-like 1 (cartilage glycoprotein-39, HC-gp39, table 3) and 
confirmed with dot blot with a mean ratio of 2.1 (not shown). 4 clones were similar to 
the transmembrane glycoprotein nmb, GPNMB (mRNA, NM_002510, table 3). 
Subtractive screening revealed another clone identified as procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 3 (PLOD3, mRNA) with the NCBI accession number 
NM_001084 (table 3 additional material).  
In addition a reverese subtraction was performed investigating genes expressed in 
control CLPF but not in CD strictures. cDNA from stricture CLPF was subtracted from 
control CLPF. After nested PCR we obtained 8 distinct bands which were cloned and 
sequenced. The finally obtained 92 clones are listed in table 4. They represent genes, 
which are downregulated during stricture formation. The complete table is given in 
additional material. 10 clones were identified as fibronectin (splice variant not 
containing ED-B domain, CDS) with the NCBI accession number HSU42457 (table 4). 3 
clones were identified as moesin mRNA with the NCBI accession number NM_002444.  
 
Comparison of CD CLPF from strictures versus non-strictured areas 
Aim of this approach was the identification of stricture specific genes. cDNA from CD 
CLPF from non-strictured areas was subtracted from cDNA from strictured areas of the 
same patient and vice versa. In contrast to the other approaches, the mRNA probes 
were not pooled. By this approach patient specific genes should not be obtained during 
subtraction. Only one distinct band was obtained after nested PCR. Table 5 gives a list 
of 10 clones that were obtained. 2 clones were identified as interleukin (IL)-8 with the 
NCBI accession number NM_000584 (mRNA). One clone was sequenced and 
determined identical to tumor rejection antigen (gp96) 1 (TRA1) (mRNA, NM_003299). 
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Lipopolysaccharide-induced TNF-alpha factor (LITAF, mRNA, NM_004862) was detected 
to be upregulated in CD CLPF from strictured areas. 
In the contrary approach, genes were identified that are expressed in CD CLPF but not 
in CLPF obtained from strictures. Six distinct bands could be obtained after nested PCR. 
After cloning, 72 plasmids were sequenced and 71 clones showed a score > 700 bits by 
comparing at the NIH gene bank. A list of the most abundant clones is given in table 6. 
The complete tables are accessable as additional material. Sequences of 8 clones were 
compatible to homo sapiens cDNA FLJ33114 fis (clone TRACH2001289) with the the 
NCBI accession number AK057676. Homo sapiens seven in absentia homolog 2 
(Drosophila, SIAH2, mRNA, NM_005067) and the WEE1 homolog (S. pombe, WEE1, 
mRNA, NM_003390) were found four times each. 
 
Affymetrix microarray analysis  
With a second independent approach gene expression of CLPF from control patients 
and non-strictured areas from CD patients was compared. The comparison was 
structured as described for subtractive hybridization. Nine affymetrix microarrays were 
hybridized (Affymetrix® GeneChip HG-U133A). Three were hybridized with mRNA from 
control CLPF, three with mRNA from stricture CLPF of CD patients and three with CLPF 
from inflamed areas of CD patients. The raw data were compared with software 
affymetrix microarray judge version 5.0.  
Table 7 gives a shortened list of genes with changes in expression in CD CLPF from 
non-strictured areas compared to control CLPF. Analysis showed upregulation of mRNA 
for immunoglobulin superfamily (member 4, Hs.70337) in CD CLPF (signal log ratio 
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3.8). Further a collagenase was found (matrix metalloproteinase 1, Hs.83169, signal log 
ratio 1.5, table 7 additional material).  
In non-strictured areas two genes were clearly upregulated. The Rho family guanine-
nucleotide exchange factor (Hs.126565) and collagen type XIV alpha 1 (undulin, 
Hs.403836) with a signal log ratio of 5.2 and 4.5 respectively. The complete table with 
34 genes with a signal log ratio >1 or <-1 is given under additional material. 
 
A list of the 10 most abundant genes expressed in CD CLPF from strictures compared to 
control CLPF is shown in table 8. The complete list of 101 genes is accessable as 
additional material. Interestingly microarray analysis showed upregulation of chitinase 
3-like 1 (signal log ratio 1.9, cartilage glycoprotein-39, HC-gp39, Hs.75184) with a 
signal log ratio of 1.9 (table 8 additional material) thus confirming subtractive 
hybridisation (table 3) and dot blot data. IL-8 (mRNA, NM_000584) was upregulated 
with a signal log ratio of 2.1 in strictures supporting the data obtained by subtractive 
hybridisation (table 5).  
Analysis of genes upregulated in CLPF from healthy areas of control patients compared 
to CLPF from strictures of patients with CD revealed four genes associated with 
collagen: CD36 antigen (collagen type I receptor, thrombospondin receptor, Hs.75613), 
collagen type XIV (alpha 1, undulin, Hs.403836), collagen type XV (alpha 1, Hs.83164) 
and collagen type I (alpha 1, Hs.172928). Further the EGF-containing fibulin-like 
extracellular matrix protein 1 (Hs.76224) and integrin beta-like 1 (with EGF-like repeat 
domains, Hs.82582) were found. 
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Next we compared genes that are differentially expressed in CD CLPF and stricture 
CLPF. A shortened list is given in table 9 headed by keratin 7 (Hs.23881) and integrin 
alpha 7 (Hs.74369) with a signal log ratio of 3.7 and 3.4 respectively. One gene was 
associated with collagen: collagen type IV (alpha 1, Hs.119129, table 9 additional 
material). Further EGF-containing fibulin-like extracellular matrix protein 1 (Hs.76224) 
was detected. Analog to the comparison of CD CLPF from strictures versus control using 
the technique of subtractive screening (table 3) this microarray analysis showed again 
upregulation of chitinase 3-like 1 (cartilage glycoprotein-39, HC-gp39) with a signal log 
ratio of 2.5 (table 9 additional material). 
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Discussion 
We compared the mRNA expression patterns of CLPF from control patients, non-
strictured areas of CD patients and strictures from CD patients. Two different methods 
of expression analysis were performed, namely subtractive hybridization and affymetrix 
microarrays. From the subtractive hybridization taken together 782 clones were isolated 
and sequenced, 656 clones resulted in appropriate sequence data. The 656 clones 
represented 278 different genes. Dot blot analysis was performed to confirm the 
results. 215 genes with known function remained out of which 131 clones were 
investigated in dot blot experiments. 88 clones were confirmed as differentially 
expressed. 11 genes were identified in independent subtractive hybridizations as 
differentially expressed. In the microarray analysis, we found results for 160 different 
transcripts. The omission of genes with unknown function resulted in 147 transcripts, 
which were differentially regulated in the investigated CLPF populations. Out of these 
147 genes, 46 genes showed up in different comparisons.  
Taken together, by subtractive hybridization, 215 differentially expressed genes could 
be identified, in the microarray analysis we found 147 genes. Three genes were found 
by both methods, namely chitinase 3-like 1 (cartilage glycoprotein-39, CHI3L1), 
glycoprotein (transmembrane) nmb (GPNMB) and IL-8.  
 
Expression of chitinase 3-like 1 was upregulated in CD CLPF from strictures 
confirmed by subtraction, microarray and dot blot analysis. Interestingly, chitinase 3-
like 1 recently was found to be significantly upregulated in inflamed colon of the 
dextran sulfate sodium (DSS)-induced colitis model by Kawada et. al. (25). Mizugichi et. 
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al. found clear expression of chitinase 3-like 1 protein in lamina propria and colonic 
epithelial cells in murine colitis models and CD patients but no expression in normal 
controls (26). Chitinase 3-like-1 has a chitin binding ability without the enzymatic 
activity of lysing microbial cell wall. It is involved in the facilitation of bacterial invasion 
into the intestinal mucosa and might contribute to the development or perpetuation of 
acute colitis in the murine DSS model. Chitinase 3-like 1 protein on the surface of CD 
CLPF from strictures might enhance the adhesion and invasion of bacteria. The 
functionality of chitinase 3-like 1 protein on human CD CLPF from strictures is currently 
not investigated. The ability of CLPF to recognize bacteria via chitinase 3-like 1 protein 
might help for a better understanding of the pathophysiology of fibrosis and might be 
the responsible mediator for the development of new therapeutic strategies. 
Recognition of bacteria could provide an explanation why proteins associated with 
inflammatory conditions are upregulated in CD CLPF from strictures. This suggestion is 
assured by our finding that IL-8, tumor rejection antigen (gp96) and the 
lipopolysaccharide-induced TNF-alpha factor were upregulated in strictures in 
subtraction and microarray analysis. A NF-kappaB dependent increase in IL-8 secretion 
by CLPF was described earlier by Lippert et. al. (15). The tumor rejection antigen 
(gp96) has been clearly associated with chaperone function for Toll-like receptors wich 
are again involved in pathogen recognition (27). 
 
Subtraction revealed fibronectin (transcript variant 1) as being upregulated in CD 
CLPF compared to control CLPF. Dot blot analysis further confirmed upregulation in 
both CLPF derived from CD and from strictures compared to control CLPF. The 
extracellular glycoprotein fibronectin is an essential factor for the induction of CLPF 
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migration. The recruitment of fibroblasts to sites of tissue injury is an initial necessity 
for optimal repair of tissue damage (28). Despite importance for wound healing CLPF 
migration is probably excessively increased in fibrotic mucosa compared to CD CLPF 
and control CLPF. Confirmative with our finding an increased amount of fibronectin in 
fibrotic mucosa of CD patients was identified in a previous study by Brenmoehl et. al. 
(29). 
Fibronectin occurs in up to 20 different isoforms as a result of alternative splicing of the 
primary transcript. In our study we found the fibronectin splice variant not containing 
ED-B domain to be upregulated in control CLPF but not in CD strictures. Alternative 
splicing mainly occurs in the two homologous type III domains named extra domain A 
(ED-A) and extra domain B (ED-B) (30-34). The ED-A and ED-B segments are either 
entirely included or excluded (35). Alternatively spliced fibronectin isoforms show 
distinct functional differences. The splicing variant ED-A plays a role in the regulation of 
cell proliferation (36) and differentiation of fibroblasts into myofibroblasts (37, 38). In 
promoting migration fibronectin ED-A is significantly more potent than fibronectin 
without ED-A domain. Brenmoehl et. al. (29) detected more fibronectin ED-A protein in 
fibrotic mucosa of CD patients compared to control mucosa. Blocking of the ED-A 
sequence potentially could reduce CLPF migration into strictures. 
 
Similar to fibronectin stricturing disease is accompanied by an increased synthesis of 
collagen type III fibrils in the intestinal mucosa. α-smooth muscle cell actin positive 
CLPF were suspected as being responsible for the increased formation of collagen (7, 
8). In our study, we found different expression patterns for certain collagen types and 
collagen modifying enzymes. CLPF from healthy areas of control patients showed 
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increased mRNA expression of collagen type I, type XIV, type XV and a collagen type I 
receptor (CD36) compared to CLPF from strictures of patients with CD. In contrast 
collagen type IV and a procollagen oxygenase are upregulated in CD CLPF derived from 
strictures. Collagen type I and a matrix metalloproteinase 1 (collagenase) were 
revealed as being upregulated in CD CLPF from non strictured areas compared to 
control CLPF. 
 
Synthesis of extracellular proteins like fibronectin and collagen could be increased in 
vitro by IGF-1, bFGF, PGDF and TGF-β1 (10, 39-41). In our study we found altered 
mRNA expression for proteins not mentioned with CD and fibrostenosis before. CD 
CLPF from healthy areas of control patients showed upregulated expression of EGF-
containing extracellular matrix protein and integrin beta-like protein with 
EGF-like domains. EGF-containing extracellular matrix protein was downregulated in 
stricture CLPF. Both matrix proteins expressed by CLPF could be part of a paracrine 
mechanism and might be able to further increase the migratory potential of CLPF. 
 
In the light of the current literature a number of interesting candidates resulted from 
the multiplicity of identified genes. In regard to the functional changes of CLPF during 
stenosis and other dysfunctions some proteins might represent a therapeutic target: 
extracellular components (fibronectin, collagen type I, collagen type IV, collagen type 
XIV, biglykan and versikan), tissue destructing enzymes (matrixmetalloproteinase 1, 
cathepsin K), IL-8, chitinase 3-like 1, glycoprotein nmb, RhoA or the stromal cell-
derived factor-1. Some proteins could also be suited as marker for disease activity or 
offer an indication for fibrostenosis evaluation (fibronectin, chitinase 3-like 1). 
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Table legends 
 
Table 1: Specimens. 9 patients with sigma-carcinoma; 1 patient with diverticulosis; 10 
patients with CD and 10 with CD-stenoses. Of a total of 30 subjects, 12 were male and 
18 were female. Patients were between 17 and 74 years of age and treated with 
budesonide, 5-ASA, azathioprine and systemic steroids. 
 
Table 2: List of genes identified to be upregulated in CLPF of patients with CD (tester) 
using the technique of subtractive screening as described. CLPF from healthy areas of 
control patients were used as driver population. Sequence similarity search was 
performed with the blast program as described in Materials and methods. Ten hits with 
a score > 700 bits are shown. Sequence similarities with a lower score are not listed in 
the table. Products verified by dot blot analysis are given as ratio of tester versus 
driver. Only hits with a ratio > 2 are shown. The experiments were performed two 
times. The full table is accessable as additional material. 
 
Table 3: Genes identified to be upregulated in CLPF from strictures of patients with CD 
(tester) using the technique of subtractive screening. CLPF from healthy areas of 
control patients were used as driver population. Products verified by dot blot analysis 
are given as ratio of tester versus driver. The experiments were performed two times. 
Complete table added as additional material. 
 
Table 4: List of genes identified to be upregulated in CLPF from healthy areas of 
control patients (tester) using the technique of subtractive screening. CLPF from 
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strictures of patients with CD were used as driver population. The experiments were 
performed two times. Full table added as additional material. 
 
Table 5: Genes identified to be upregulated in CLPF from strictures of a patient with 
CD (tester) using the technique of subtractive screening. CLPF from non-strictured 
areas of the same patient with CD were used as driver population. The experiments 
were performed two times. Complete table see additional material. 
 
Table 6: List of genes identified to be upregulated in CLPF from patients with CD 
(tester) using the technique of subtractive screening. CLPF from strictures of the same 
patient with CD were used as driver population. The experiments were performed two 
times. Full table see additional material. 
 
Table 7: Changed expression in CD CLPF versus CLPF from healthy areas of control 
patients identified using the technique of affymetrix® microarray analysis. Genes are 
listed using the NIH UniGene coding. Signal log ratio was calculated as mean from 
three different analyses. Multiple entry of certain genes is caused by GeneChip® layout 
detecting transcript variants. The full table is accessable as additional material. 
 
Table 8: List of genes with changed expression in CD CLPF from strictures versus CLPF 
from healthy areas of control patients (affymetrix® microarray analysis). Complete table 
added as additional material. 
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Table 9: Changed expression in CD CLPF from strictures versus CD CLPF from the 
same patient (affymetrix® microarray analysis). Full table added. 
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Figure legends 
 
Figure 1: Dot blot analysis. Fibronectin cDNA blotted on a membrane was hybridized 
with 32-P dATP labeled tester and driver respectively. Quantified signals, normalized to 
the house keeping genes confirmed upregulation of fibronectin mRNA in (A) CD CLPF 
and (B) CLPF from patients with CD-stenosis versus CLPF from non-inflamed patients 
(ratio tester versus driver 143 and 63 respectively). Dot blot experiments were 
performed three times. 
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 gende
r 
age disease disease behavior treatment used for basis 
1 m 64 sigma-carcinoma no inflammation n. d. subtractive screening CLPF 
2 m 62 sigma-carcinoma no inflammation n. d. subtractive screening CLPF 
3 f 59 sigma-carcinoma no inflammation n. d. subtractive screening CLPF 
4 m 32 sigma-carcinoma no inflammation n. d.   
5 f 32 CD no inflammation - subtractive screening CLPF 
6 m 19 CD mild inflammation budesonide subtractive screening CLPF 
7 m 28 CD mild inflammation azathioprine subtractive screening CLPF 
8 f 36 CD no inflammation -   
9 f 58 CD-stenoses severe inflammation / 
fibrotic 
5-ASA subtractive screening CLPF 
10 f 32 CD-stenoses mild inflammation azathioprine subtractive screening CLPF 
11 m 28 CD-stenoses mild inflammation azathioprine subtractive screening CLPF 
12 f 32 CD-stenoses severe inflammation azathioprine, 5-ASA subtractive screening CLPF 
13 m 61 sigma-carcinoma no inflammation n. d. microarray analysis CLPF 
14 m 58 sigma-carcinoma no inflammation n. d. microarray analysis CLPF 
15 f 74 sigma-carcinoma no inflammation n. d. microarray analysis CLPF 
16 f 33 CD no inflammation - microarray analysis CLPF 
17 f 32 CD no inflammation - microarray analysis CLPF 
18 m 19 CD mild inflammation budesonide microarray analysis CLPF 
19 f 34 CD-stenoses mild inflammation systemic steroids,  
5-ASA 
microarray analysis CLPF 
20 f 36 CD-stenoses mild inflammation systemic steroids,  
5-ASA 
microarray analysis CLPF 
21 f 58 CD-stenoses severe inflammation / 
fibrotic 
5-ASA microarray analysis CLPF 
22 f 70 sigma-carcinoma no inflammation n. d. dot blot CLPF 
23 m 23 Sigma-
diverticulosis 
severe inflammation n. d. dot blot CLPF 
24 m 66 sigma-carcinoma no inflammation n. d. dot blot CLPF 
25 f 53 CD no inflammation systemic steroids dot blot CLPF 
26 f 52 CD n. d. - dot blot CLPF 
27 m 26 CD severe inflammation azathioprine, 5-ASA dot blot CLPF 
28 f 28 CD-stenoses no inflammation - dot blot CLPF 
29 f 31 CD-stenoses mild inflammation systemic steroids,  
5-ASA 
dot blot CLPF 
30 f 17 CD-stenoses mild inflammation azathioprine dot blot CLPF 
 
Table 1 
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Identity of differentially expressed clones NCBI 
accession 
no. 
Number 
of hits 
ratio CD 
vs. 
control 
Fibronectin 1 (FN1), transcript variant 1, mRNA NM_002026 5 143 
Splicing factor (CC1.4) mRNA, complete cds L10911 5 60 
Cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11), mRNA NM_033664 1 55 
Voltage-dependent anion channel 3 (VDAC3), mRNA NM_005662 7 47 
Homo sapiens CD59 antigen p18-20 (antigen identified by 
monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) 
(CD59), mRNA 
NM_000611 4 23 
Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
(ITGA5), mRNA 
NM_002205 1 22 
Cathepsin K (pycnodysostosis) (CTSK), mRNA NM_000396 1 20 
Collagen, type I, alpha 2 (COL1A2), mRNA NM_000089 1 17 
Homo sapiens chromosome 8 clone RP11-429D14 map 8q24.2. AF254981 10 17 
Claudin 1 (CLDN1), mRNA NM_021101 3 16 
Table 2 
 
Identity of differentially expressed clones NCBI 
accession 
no. 
Number 
of hits 
ratio 
stenosis 
vs. 
contro 
MpV17 transgene, murine homolog, glomerulosclerosis 
(MPV17), mRNA 
NM_002437 1 102 
Tetraspan 2 (TSPAN-2), mRNA NM_005725 1 86 
Butyrophilin, subfamily 2, member A1 (BTN2A1), transcript 
variant 2 
NM_078476 4 71 
Thioredoxin interacting protein (TXNIP), mRNA NM_006472 12 10 
Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), 
mRNA 
NM_001402 5 8.6 
Humanin (HN1) mRNA, complete cds AY029066 5 6.6 
Progesterone receptor membrane component 2 (PGRMC2), 
mRNA 
NM_006320 3 4.9 
Nucleostemin (NS), mRNA NM_014366 5 3.8 
Glycoprotein (transmembrane) nmb (GPNMB), mRNA NM_002510 4 n.a 
Homo sapiens chitinase 3-like 1 (cartilage glycoprotein-39), 
mRNA (cDNA clone MGC:17246 IMAGE:4183798), complete cds
BC039132 5 2.1 
Table 3 
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Identity of differentially expressed clones NCBI 
accession 
no. 
Number 
of hits 
Human fibronectin (FN1) mRNA, splice variant not containing 
EIIIB domain, CDS 
HSU42457 10 
Phosphofurin acidic cluster sorting protein 1 (PACS1), mRNA NM_018026 5 
Geal-6 membrane-associated high-copy suppressor 1 (GMH1), 
mRNA  
NM_014044 5 
Moesin (MSN), mRNA NM_002444 3 
Calcipressin 1 large isoform (DSCR1) mRNA, complete cds AY325903 3 
Amyloid beta (A4) precursor-like protein 2 (APLP2), mRNA NM_001642 3 
Nucleostemin (NS), mRNA NM_014366 3 
Hypothetical protein LOC130074 (LOC130074), mRNA XM_072228 3 
Homo sapiens mRNA for KIAA0393 protein, partial cds AB002391 2 
Trafficking protein particle complex 4 (TRAPPC4), mRNA NM_016146 2 
Table 4 
 
Identity of differentially expressed clones NCBI 
accession 
no. 
Number 
of hits 
Interleukin 8 (IL8), mRNA NM_000584 2 
Sarcolemmal associated protein 1 mRNA,complete cds, 
alternatively spliced 
AF304450 1 
Mixed lineage kinase-related kinase MRK-beta mRNA, complete 
cds 
AF480462 1 
Tumor rejection antigen (gp96) 1 (TRA1), mRNA NM_003299 1 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, beta polypeptide (YWHAB), transcript variant 
1,mRNA 
NM_003404 1 
NCK-associated protein 1 (NCKAP1), mRNA NM_205842 1 
Fucosidase, alpha-L-2, plasma (FUCA2), mRNA NM_032020 1 
Lipopolysaccharide-induced TNF-alpha factor (LITAF), mRNA NM_004862 1 
Homo sapiens mRNA; cDNA DKFZp686H19148 (from clone 
DKFZp686H19148)  
BX648835 1 
Human DNA sequence from clone RP4-753C8 on chromosome 
1p31.3-32.3, complete sequence  
AL139255 1 
Table 5 
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Identity of differentially expressed clones NCBI 
accession 
no. 
Number 
of hits 
Homo sapiens cDNA FLJ33114 fis, clone TRACH2001289 AK057676 8 
Homo sapiens seven in absentia homolog 2 (Drosophila) 
(SIAH2), mRNA 
NM_005067 4 
WEE1 homolog (S. pombe) (WEE1), mRNA NM_003390 4 
Replication protein A1, 70kDa (RPA1), mRNA NM_002945 3 
ATPase, Na+/K+ transporting, beta 1 polypeptide(ATP1B1),mRNA NM_001677 3 
Homo sapiens REV3-like, catalytic subunit of DNA polymerase 
zeta (yeast) (REV3L), mRNA 
NM_002912 2 
Transmembrane 4 superfamily member 10 (TM4SF10), mRNA NM_031442 2 
Angiopoietin-like 2 (ANGPTL2), mRNA NM_012098 2 
Enolase 1, (ENO1), mRNA NM_001428 2 
Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
(ITGA5), mRNA 
NM_002205 2 
Table 6 
 
Identity of differentially expressed genes Unigene 
no. 
Signal 
log 
ratio 
Genes upregulated in CD CLPF compared to CLPF from healthy areas of control patients 
1 immunoglobulin superfamily, member 4 Hs.70337 3.8 
2 fatty acid binding protein 5 (psoriasis-associated) Hs.408061 3.0 
3 brain expressed, X-linked 1 Hs.334370 2.3 
4 Ras-induced senescence 1 Hs.35861 2.1 
5 caveolin 1, caveolae protein, 22kDa Hs.74034 1.7 
Genes upregulated in CLPF from healthy areas of control patients compared to CD CLPF 
1 Rho family guanine-nucleotide exchange factor Hs.126565 -5.2 
2 collagen, type XIV, alpha 1 (undulin) Hs.403836 -4.5 
3 Homo sapiens cDNA FLJ20286 fis, clone HEP04358. Hs.434483 -3.5 
4 alcohol dehydrogenase IB (class I), beta polypeptide Hs.4 -3.3 
5 chemokine (C-C motif) ligand 11 Hs.54460 -3.2 
Table 7 
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Identity of differentially expressed genes Unigene 
no. 
Signal 
log 
ratio 
Genes upregulated in CLPF from strictures of patients with CD compared to CLPF from healthy areas of 
control patients 
1 hypothetical protein FLJ14146 Hs.103395 4.5 
2 neuroligin Hs.21107 4.5 
3 chemokine (C-X-C motif) ligand 14 Hs.24395 4.0 
4 CD14 antigen Hs.75627 3.1 
5 collectin sub-family member 12 Hs.29423 3.0 
Genes upregulated in CLPF from healthy areas of control patients compared to CLPF from strictures of 
patients with CD 
1 Rho family guanine-nucleotide exchange factor Hs.126565 -4.5 
2 matrix Gla protein Hs.365706 -4.3 
3 keratin 7 Hs.23881 -3.9 
4 Homo sapiens cDNA FLJ20286 fis, clone HEP04358. Hs.434483 -3.4 
5 integrin, alpha 7 Hs.74369 -2.9 
Table 8 
 
 
 
Identity of differentially expressed genes Unigene 
no. 
Signal 
log 
ratio 
Genes upregulated in CLPF from CD CLPF compared to strictures from the same patient 
1 keratin 7 Hs.23881 3.7 
2 integrin, alpha 7 Hs.74369 3.4 
3 butyrylcholinesterase Hs.1327 2.6 
4 fatty acid binding protein 5 (psoriasis-associated) Hs.408061 2.6 
5 EGF-containing fibulin-like extracellular matrix protein 1 Hs.76224 2.0 
Genes upregulated in CLPF from strictures of patients with CD compared to CD CLPF from the same 
patient 
1 hypothetical protein FLJ14146 Hs.103395 -4.8 
2 plexin C1 Hs.286229 -3.5 
3 complement component 3 Hs.284394 -3.5 
4 CD24 antigen (small cell lung carcinoma cluster 4 antigen) Hs.375108 -3.5 
5 G protein-coupled receptor, family C, group 5, member B Hs.242407 -3.4 
Table 9 
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Additional Material 
Table legends 
 
Table 2 (additional material): List of genes identified to be upregulated in CLPF of 
patients with CD (tester) using the technique of subtractive screening as described. 
CLPF from healthy areas of control patients were used as driver population. Sequence 
similarity search was performed with the blast program as described in Materials and 
methods. Products verified by dot blot analysis are given as ratio of tester versus 
driver. The experiments were performed two times. 
 
Table 3 (additional material): Genes identified to be upregulated in CLPF from 
strictures of patients with CD (tester) using the technique of subtractive screening. 
CLPF from healthy areas of control patients were used as driver population. Products 
verified by dot blot analysis are given as ratio of tester versus driver. The experiments 
were performed two times. 
 
Table 4 (additional material): List of genes identified to be upregulated in CLPF 
from healthy areas of control patients (tester) using the technique of subtractive 
screening. CLPF from strictures of patients with CD were used as driver population. The 
experiments were performed two times. 
 
Table 5 (additional material): List of genes identified to be upregulated in CLPF 
from strictures of a patient with CD (tester) using the technique of subtractive 
screening. CLPF from non-strictured areas of the same patient with CD were used as 
driver population. The experiments were performed two times. 
 
Table 6 (additional material): Genes identified to be upregulated in CLPF from 
patients with CD (tester) using the technique of subtractive screening. CLPF from 
strictures of the same patient with CD were used as driver population. The experiments 
were performed two times. 
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Table 7 (additional material): List of genes with changed expression in CD CLPF 
versus CLPF from healthy areas of control patients. Genes are listed using the NIH 
UniGene coding. Signal log ratio was calculated as mean from three different analyses. 
Multiple entry of certain genes is caused by GeneChip® layout detecting transcript 
variants.  
 
Table 8 (additional material): List of genes with changed expression in CD CLPF 
from strictures versus CLPF from healthy areas of control patients. 
 
Table 9 (additional material): Genes with changed expression in CD CLPF from 
strictures versus CD CLPF from the same patient.  
 
Table 10 (additional material): List of genes with expression identified to be either 
up- or downregulated in a tester population compared to two driver populations using 
the technique of subtractive screening. 
Lang et al        Gene expression profiles of mucosal fibroblasts from CD strictures  
 
35
 
Identity of differentially expressed clones NCBI 
accession no. 
Number 
of hits 
ratio CD
vs. 
control 
Isoleucine-tRNA synthetase (IARS), transcript variant long, 
mRNA 
NM_013417 11 4.0 
Homo sapiens chromosome 8 clone RP11-429D14 map 8q24.2, 
complete sequence 
AF254981 10 17 
Humanin (HN1) mRNA, complete cds AY029066 9 9.9 
Voltage-dependent anion channel 3 (VDAC3), mRNA NM_005662 7 47 
Hypothetical protein KIAA1259 (KIAA1259), mRNA NM_032196 7 7.8 
Lysosomal-associated protein transmembrane 4 alpha 
(LAPTM4A), mRNA 
NM_014713 6 34 
Thyroid autoantigen 70kDa (Ku antigen) (G22P1), mRNA NM_001469 6 5.3 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 10 (RNA 
helicase) (DDX10), mRNA 
NM_004398 6 3.8 
Homo sapiens mitochondrial genome  V00662 6 2.1 
Fibronectin 1 (FN1), transcript variant 1, mRNA NM_002026 5 143 
Splicing factor (CC1.4) mRNA, complete cds L10911 5 60 
Heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa) (HSPA5), mRNA 
NM_005347 5 4.1 
Homo sapiens CD59 antigen p18-20 (antigen identified by 
monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) 
(CD59), mRNA 
NM_000611 4 23 
NUMB protein mRNA, complete cds AF108092 4 2.2 
Ring finger protein 19 (RNF19), mRNA NM_015435 3 7.9 
Claudin 1 (CLDN1), mRNA NM_021101 3 16 
Similar to tubulin tyrosine ligase, clone IMAGE:3865811, mRNA BC036331 3 2.5 
TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 250kDa (TAF1), transcript variant 2, mRNA 
NM_138923 3 28 
Heme binding protein 2 (HEBP2), mRNA NM_014320 3 1.0 
Poly(A) binding protein, cytoplasmic 1 (PABPC1), mRNA NM_002568 3 7.2 
Homo sapiens likely ortholog of mouse monocyte macrophage 
19 (MMRP19), mRNA 
NM_015957 3 2.3 
Hypothetical protein DKFZp313M0720 (DKFZp313M0720), 
mRNA 
XM_113743 2 1.3 
Similar to thioredoxin interacting protein, clone 
IMAGE:4901203, mRNA 
BC024305 2 0.2 
Down syndrome critical region gene 1 (DSCR1), mRNA NM_004414 2 40 
Development and differentation enhancing factor 2 (DDEF2), 
mRNA 
NM_003887 2 2.1 
Translin (TSN), mRNA NM_004622 2 1.2 
Tubulin, beta, 2 (TUBB2), mRNA NM_006088 2 18 
Homo sapiens mRNA for KIAA1333 protein, partial cds AB037754 2 2.3 
Human DNA sequence from clone CTD-2530H13 on 
chromosome X, complete sequence 
AL513007 2 6.1 
Putative L-type neutral amino acid transporter (KIAA0436), 
mRNA 
XM_010822 2 3.4 
Karyopherin alpha 4 (importin alpha 3) (KPNA4), mRNA NM_002268 2 28 
Glutathione S-transferase pi (GSTP1), mRNA NM_000852 2 9.0 
Prothymosin, alpha (gene sequence 28) (PTMA), mRNA NM_002823 2 1.1 
Phosphatidylinositol-3 phosphate 3-phosphatase adaptor 
subunit (3PAP), mRNA 
NM_019061 2 1.1 
Ribosomal protein S16 (RPS16), mRNA NM_001020 2 12 
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Human DNA sequence from clone RP3-486L4 on chromosome 
6q14.3-16.1, complete sequence 
AL133211 2 3.9 
Ribosomal protein L41 (RPL41), mRNA NM_021104 2 16 
Similar to hypothetical protein FLJ35882 [Homo sapiens] 
(LOC132689), mRNA 
XM_067981 2 41 
Ribosomal protein L13a (RPL13A), mRNA NM_012423 1 1.9 
Homo sapiens mRNA for KIAA0100 protein, partial cds D43947 1 41 
Cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11), mRNA NM_033664 1 55 
Hypothetical protein FLJ10350 (FLJ10350), mRNA NM_018067 1 39 
Signal transducer and activator of transcription 3 interacting 
protein 1 (STATIP1), mRNA 
NM_018255 1 45 
LIM domain kinase 2 (LIMK2), transcript variant 2a, mRNA NM_005569 1 3.7 
Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
(ITGA5), mRNA 
NM_002205 1 22 
Collagen, type I, alpha 2 (COL1A2), mRNA NM_000089 1 17 
Rab interacting lysosomal protein, clone MGC:34119 
IMAGE:5174974, mRNA, complete cds 
BC031621 1 0.6 
N-myristoyltransferase 2 (NMT2), mRNA NM_004808 1 1.3 
Cathepsin K (pycnodysostosis) (CTSK), mRNA NM_000396 1 20 
Nucleostemin (NS), mRNA NM_014366 1 7.5 
Growth hormone inducible transmembrane protein (GHITM), 
mRNA 
NM_014394 1 37 
Palmitoyl-protein thioesterase 1 (ceroid-lipofuscinosis, 
neuronal 1, infantile) (PPT1), mRNA 
NM_000310 1 34 
Homo sapiens mRNA for fibulin-4 AJ132819 1 5.0 
Copine III (CPNE3), mRNA NM_003909 1 88 
GRB2-associated binding protein 3 (GAB3), mRNA NM_080612 1 50 
Dendritic cell protein (GA17), mRNA NM_006360 1 26 
Sp3 transcription factor (SP3), mRNA XM_092672 1 4.7 
Acid cluster protein 33 (ACP33), mRNA NM_016630 1 5.4 
Eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1), 
mRNA 
NM_001416 1 1.9 
PDZ domain containing guanine nucleotide exchange factor 
(GEF) 1 (PDZ-GEF1), mRNA 
NM_014247 1 26 
Methionine synthase mRNA, complete cds HSU73338 1 67 
Synaptophysin-like protein (SYPL), mRNA NM_006754 1 43 
Aldo-keto reductase family 1, member B1 (aldose reductase) 
(AKR1B1), mRNA 
NM_001628 1 7.5 
Oxysterol binding protein-like 8 (OSBPL8), mRNA NM_020841 1 10 
KARP-1-binding protein (KAB), mRNA NM_014812 1 24 
Golgi reassembly stacking protein 2, 55kDa (GORASP2), mRNA NM_015530 1 5.0 
Gelsolin (amyloidosis, Finnish type) (GSN), transcript variant 1, 
mRNA 
NM_000177 1 0.7 
Cyclin D binding myb-like transcription factor 1 (DMTF1), 
mRNA 
NM_021145 1 4.1 
Nucleoporin like 1 (NUPL1), mRNA NM_014089 1 0.4 
Homo sapiens Sec23 homolog B (S. cerevisiae), mRNA NM_032986 1 1.4 
Ferritin, light polypeptide (FTL), mRNA NM_000146 1 3.9 
Actin related protein 2/3 complex, subunit 2, 34kDa (ARPC2), 
transcript variant 1, mRNA 
NM_152862 1 1.5 
Myotubularin related protein 4 (MTMR4), mRNA NM_004687 1 2.5 
Surfeit 4 (SURF4), mRNA NM_033161 1 10 
Ribosomal protein S6 (RPS6), mRNA NM_001010 1 14 
Actin, gamma 1 (ACTG1), mRNA NM_001614 1 1.1 
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ADP-ribosylation factor 5 (ARF5), mRNA NM_001662 1 41 
Transcription factor 21 (TCF21), mRNA NM_003206 1 18 
Tumor endothelial marker 8 (TEM8), transcript variant 1, 
mRNA 
NM_032208 1 35 
Leucyl-tRNA synthetase (LARS), mRNA NM_020117 1 27 
Homo sapiens mRNA; cDNA DKFZp686M1316 (from clone 
DKFZp686M1316) 
AL832178 1 38 
Homo sapiens chromosome 17, clone RP13-638C3, complete 
sequence 
AC124283 1 8.1 
Human DNA sequence from clone RP4-786G8 on chromosome 
1, complete sequence 
AL731797 1 59 
Homo sapiens BAC clone RP11-348G16 from 2, complete 
sequence 
AC010095 1 31 
Homo sapiens 12 BAC RP11-588H23 (Roswell Park Cancer 
Institute Human BAC Library) complete sequence 
AC025569 1 5.2 
Homo sapiens, clone IMAGE:4860149, mRNA BC025313 1 57 
Hypothetical protein MGC4767 (MGC4767), mRNA NM_032314 1 0.5 
Homo sapiens BAC clone RP11-480A6 from 2, complete 
sequence 
AC016912 1 21 
Ribosomal protein S7 (RPS7), mRNA NM_001011 1 39 
Amyloid beta (A4) precursor protein (protease nexin-II, 
Alzheimer disease) (APP), mRNA 
NM_000484 1 41 
 
Table 2 (additional material) 
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Identity of differentially expressed clones NCBI 
accession no. 
Number 
of hits 
ratio CD
vs. 
control 
Prefoldin 4 (PFDN4), mRNA NM_002623 40 1.4 
Thioredoxin interacting protein (TXNIP), mRNA NM_006472 12 10 
Glucan (1,4-alpha-), branching enzyme 1 (glycogen branching 
enzyme, Andersen disease, glycogen storage disease type IV) 
(GBE1), mRNA 
NM_000158 10 2.7 
Homo sapiens BAC clone RP11-809N18 from 4, complete 
sequence 
AC058822 5 1.2 
Homo sapiens BAC clone RP11-307I2 from 7, complete 
sequence 
AC099548 5 n.d. 
Humanin (HN1) mRNA, complete cds AY029066 5 6.6 
Homo sapiens chitinase 3-like 1 (cartilage glycoprotein-39), 
mRNA (cDNA clone MGC:17246 IMAGE:4183798), complete 
cds 
BC039132 5 2.1 
Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), 
mRNA 
NM_001402 5 8.6 
Tyrosylprotein sulfotransferase 1 (TPST1), mRNA NM_003596 5 4.5 
Protein kinase C and casein kinase substrate in neurons 2 
(PACSIN2), mRNA 
NM_007229 5 0.9 
Nucleostemin (NS), mRNA NM_014366 5 3.8 
Ribosomal protein S18 (RPS18), mRNA NM_022551 5 1.1 
Homo sapiens chromosome 8 clone RP11-429D14 map 8q24.2, 
complete sequence 
AF254981 4 2.4 
Homo sapiens CD59 antigen p18-20 (antigen identified by 
monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) 
(CD59), mRNA 
NM_000611 4 n.d. 
Glycoprotein (transmembrane) nmb (GPNMB), mRNA NM_002510 4  
Short-chain dehydrogenase/reductase 1 (SDR1), mRNA NM_004753 4 9.1 
Isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), mRNA NM_005896 4 7.0 
Homolog of yeast long chain polyunsaturated fatty acid 
elongation enzyme 2 (HELO1), mRNA 
NM_021814 4 1.4 
Butyrophilin, subfamily 2, member A1 (BTN2A1), transcript 
variant 2, mRNA 
NM_078476 4 71 
Cytochrome c oxidase II (MTCO2), mRNA NM_173705 4 n.d. 
Human DNA sequence from clone RP11-427L15 on 
chromosome 10, complete sequence 
AL139407 3 n.d. 
Homo sapiens, ras homolog gene family, member A, clone 
MGC:2330 IMAGE:3051460, mRNA, complete cds 
BC001360 3 1.5 
Isopentyl-diphosphate delta isomerase, clone MGC:24595 
IMAGE:4243851, mRNA, complete cds 
BC022418 3 1.6 
Amyloid beta (A4) precursor protein (protease nexin-II, 
Alzheimer disease) (APP), mRNA 
NM_000484 3 0.5 
Ribosomal protein L5 (RPL5), mRNA NM_000969 3 0.9 
Progesterone receptor membrane component 2 (PGRMC2), 
mRNA 
NM_006320 3 4.9 
Peroxiredoxin 3 (PRDX3), nuclear gene encoding mitochondrial 
protein, transcript variant 1, mRNA 
NM_006793 3 n.d. 
XPA binding protein 1 (MBDin), mRNA NM_007266 3 n.d. 
Plasminogen activator, tissue (PLAT), transcript variant 3, 
mRNA 
NM_033011 3 n.d. 
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Peptidylglycine alpha-amidating monooxygenase (PAM), 
transcript variant 4, mRNA 
NM_138822 3 n.d. 
Cytochrome c oxidase I (MTCO1), mRNA NM_173704 3 1.8 
Hypothetical protein DKFZp313M0720 (DKFZp313M0720), 
mRNA 
XM_113743 3 3.1 
Homo sapiens BAC clone RP11-462M9 from 2, complete 
sequence 
AC017079 2 0.8 
Human DNA sequence from clone RP11-365P13 on 
chromosome 13, complete sequence 
AL442128 2 0.9 
Homo sapiens genomic DNA, chromosome 11q, clone:CMB9-
55L24, complete sequences 
AP000642 2 0.9 
Ferritin, heavy polypeptide 1, clone MGC:17216 
IMAGE:3848510, mRNA, complete cds 
BC016857 2 n.d. 
Thioredoxin reductase 1, clone MGC:9145 IMAGE:3883490, 
mRNA, complete cds 
BC018122 2 1.1 
Similar to tubulin tyrosine ligase, clone IMAGE:3865811, mRNA BC036331 2 1.7 
Cathepsin K (pycnodysostosis) (CTSK), mRNA NM_000396 2 3.8 
Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha 
isoform (calcineurin A alpha) (PP3CA), mRNA 
NM_000944 2 1.6 
Ribosomal protein L23a (RPL23A), mRNA NM_000984 2 2.9 
Actin, gamma 1 (ACTG1), mRNA NM_001614 2 6.9 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mRNA NM_002046 2 1.2 
Aconitase 1, soluble (ACO1), mRNA NM_002197 2 n.d. 
Adenylate cyclase 3 (ADCY3), mRNA NM_004036 2 1.8 
Voltage-dependent anion channel 3 (VDAC3), mRNA NM_005662 2 n.d. 
TAR DNA binding protein (TARDBP), mRNA NM_007375 2 n.d. 
Homo sapiens chromosome 6 open reading frame 53 
(C6orf53), mRNA 
NM_016462 2 n.d. 
Hypothetical protein FLJ11259 (FLJ11259), mRNA NM_018370 2 2.7 
Hypothetical protein FLJ11273 (FLJ11273), mRNA NM_018374 2 0.8 
Autophagy Apg3p/Aut1p-like (APG3), mRNA NM_022488 2 1.4 
Hypothetical protein FLJ14525 (FLJ14525), mRNA NM_032800 2 2.5 
Homo sapiens mitochondrial genome V00662 2 1.3 
Homo sapiens mRNA for KIAA0393 protein, partial cds AB002391 1 n.d. 
BAC clone RP5-1125K23 from 7, complete sequence AC004971 1 1.3 
Homo sapiens BAC clone RP11-278G12 from 2, complete 
sequence 
AC006369 1 3.9 
Homo sapiens 12 BAC RP11-968A15 (Roswell Park Cancer 
Institute Human BAC Library) complete sequence 
AC078778 1 0.6 
Peroxisomal phytanoyl-CoA alpha-hydroxylase (PAHX) mRNA, 
complete cds 
AF023462 1 n.d. 
Homo sapiens cDNA FLJ14899 fis, clone PLACE1005055 AK027805 1 n.d. 
Human DNA sequence from clone RP4-657D16 on 
chromosome 1p32.2-34.2 Contains part of the NRD1 
(nardilysin (N-arginine dibasic convertase) ) gene, a novel 
mRNA, ESTs, STSs, GSSs and CpG Islands.n, complete 
sequence 
AL050343 1 0.9 
Human DNA sequence from clone RP5-852M4 on chr. 20. 
Contains the gene coding the HBV associated factor, anovel 
gene similar to Drosophila CG17883, a putative novel gene, 
two CpG islands, ESTs, GSSs, and STSs, complete sequence 
AL121747 1 n.d. 
Human DNA sequence from clone CTA-520D8 on chromosome 
1, complete sequence 
AL359771 1 n.d. 
Human DNA sequence from clone RP11-403A15 on 
chromosome 9, complete sequence 
AL445925 1 0.4 
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Multidrug resistance-associated protein (ABCC4) mRNA, 
complete cds 
AY081219 1 1.3 
Homo sapiens, clone IMAGE:3906774, mRNA BC020164 1 25 
Homo sapiens, clone IMAGE:4133024, mRNA BC035980 1 9.0 
Tumor necrosis factor type 1 receptor associated protein 
(TRAP2) mRNA, complete cds 
HSU12596 1 0,5 
Propionyl Coenzyme A carboxylase, alpha (PCCA), mRNA NM_000282 1 n.d. 
Ribosomal protein L9 (RPL9), mRNA NM_000661 1 1.2 
ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), 
mRNA 
NM_000701 1 n.d. 
Guanylate kinase 1 (GUK1), mRNA NM_000858 1 1.5 
Ribosomal protein L4 (RPL4), mRNA NM_000968 1 2.0 
Ribosomal protein L7a (RPL7A), mRNA NM_000972 1 1.8 
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3), 
mRNA 
NM_001084 1 n.d. 
Aldehyde oxidase 1 (AOX1), mRNA NM_001159 1 2.1 
Cyclin-dependent kinase 8 (CDK8), mRNA NM_001260 1 7.5 
Eukaryotic translation elongation factor 1 gamma (EEF1G), 
mRNA 
NM_001404 1 2.5 
Amyloid beta (A4) precursor-like protein 2 (APLP2), mRNA NM_001642 1 n.d. 
Archain 1 (ARCN1), mRNA NM_001655 1 5.2 
Lactate dehydrogenase B (LDHB), mRNA NM_002300 1 1.6 
MpV17 transgene, murine homolog, glomerulosclerosis 
(MPV17), mRNA 
NM_002437 1 102 
Polymerase (DNA directed), beta (POLB), mRNA NM_002690 1 n.d. 
S100 calcium binding protein A10 (annexin II ligand, calpactin 
I, light polypeptide (p11) ) (S100A10), mRNA 
NM_002966 1 3.6 
Tumor protein, translationally-controlled 1 (TPT1), mRNA NM_003295 1 2.7 
High mobility group AT-hook 2 (HMGA2), mRNA NM_003483 1 1.6 
Glia maturation factor, beta (GMFB), mRNA NM_004124 1 25 
Pituitary tumor-transforming 1 interacting protein (PTTG1IP), 
mRNA 
NM_004339 1 n.d. 
Cytochrome c oxidase subunit VIc (COX6C), mRNA NM_004374 1 1.7 
Down syndrome critical region gene 1 (DSCR1), transcript 
variant 1, mRNA 
NM_004414 1 n.d. 
Translin (TSN), mRNA NM_004622 1 n.d. 
Calpain 1, (mu/I) large subunit (CAPN1), mRNA NM_005186 1 0.5 
Dmx-like 1 (DMXL1), mRNA NM_005509 1 0.9 
Lactate dehydrogenase A (LDHA), mRNA NM_005566 1 1.2 
Tetraspan 2 (TSPAN-2), mRNA NM_005725 1 86 
Lipoma HMGIC fusion partner-like 2 (LHFPL2), mRNA NM_005779 1 n.d. 
Apoptosis inhibitor 5 (API5), mRNA NM_006595 1 0.7 
Methylene tetrahydrofolate dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase (MTHFD2), nuclear 
gene encoding mitochondrial protein, mRNA 
NM_006636 1 n.d. 
F-box and leucine-rich repeat protein 3A (FBXL3A), mRNA NM_012158 1 16 
Splicing factor 3b, subunit 1, 155kDa (SF3B1), mRNA NM_012433 1 n.d. 
Isoleucine-tRNA synthetase (IARS), transcript variant long, 
mRNA 
NM_013417 1 0.8 
CCR4-NOT transcription complex, subunit 2 (CNOT2), mRNA NM_014515 1 0.9 
UBX domain containing 2 (UBXD2), mRNA NM_014607 1 6.0 
S100 calcium-binding protein A6 (calcyclin) (S100A6), mRNA NM_014624 1 0.6 
Protein phosphatase methylesterase-1 (PME-1), mRNA NM_016147 1 n.d. 
Selenoprotein T (SELT), mRNA NM_016275 1 1.4 
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Stromal cell derived factor receptor 1 (SDFR1), mRNA NM_017455 1 0.6 
Homo sapiens chromosome 6 open reading frame 96 
(C6orf96), mRNA 
NM_017909 1 6.1 
Homo sapiens enabled homolog (Drosophila) (ENAH), mRNA NM_018212 1 1.6 
Mitochondrial translational release factor 1-like (MTRF1L), 
mRNA 
NM_019041 1 1.1 
Homo sapiens chromosome 9 open reading frame 19 
(C9orf19), mRNA 
NM_022343 1 n.d. 
Hypothetical protein MGC3047 (MGC3047), mRNA NM_032348 1 1.0 
Poly(A) polymerase alpha (PAPOLA), mRNA NM_032632 1 n.d. 
Hypothetical protein FLJ14775 (FLJ14775), mRNA NM_032837 1 1.6 
T-cell activation protein (PGR1), mRNA NM_033296 1 46 
Transcriptional coactivator tubedown-100 (TBDN100), 
transcript variant 1, mRNA 
NM_057175 1 n.d. 
Homo sapiens RAD50 homolog (S. cerevisiae) (RAD50), mRNA NM_133482 1 2.7 
Hypothetical protein LOC119587 (LOC119587), mRNA XM_058409 1 2.6 
Homo sapiens LOC150421 (LOC150421), mRNA XM_097901 1 0.9 
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Identity of differentially expressed clones NCBI 
accession no. 
Number of 
hits 
Human fibronectin (FN1) mRNA, splice variant not containing 
EIIIB domain, partial cds 
HSU42457 10 
Phosphofurin acidic cluster sorting protein 1 (PACS1), mRNA NM_018026 5 
Geal-6 membrane-associated high-copy suppressor 1 (GMH1), 
mRNA  
NM_014044 5 
Moesin (MSN), mRNA NM_002444 3 
Calcipressin 1 large isoform (DSCR1) mRNA, complete cds AY325903 3 
Amyloid beta (A4) precursor-like protein 2 (APLP2), mRNA NM_001642 3 
Nucleostemin (NS), mRNA NM_014366 3 
Hypothetical protein LOC130074 (LOC130074), mRNA XM_072228 3 
Human DNA sequence from clone RP3-331H24 on chromosome 
6 Contains a putative novel gene, part of the gene for 
hypothetical protein FLJ21079, similar to opioid growth factor 
receptor, ESTs, STSs, GSSs and a CpG island, complete 
sequence 
AL136164 2 
Hypothetical protein DKFZp313M0720 (DKFZp313M0720), mRNA XM_113743 2 
Peroxisomal phytanoyl-CoA alpha-hydroxylase (PAHX) mRNA, 
complete cds 
AF023462 2 
Homo sapiens mRNA for KIAA0393 protein, partial cds AB002391 2 
Homo sapiens BAC clone RP11-462M9 from 2, complete 
sequence 
AC017079 2 
Homo sapiens chromosome 17, clone hRPK.746_E_8, complete 
sequence 
AC005358 2 
Elongation of very long chain fatty acids protein-like protein 2 
(ELOVL2) mRNA, complete cds 
AF338241 2 
Trafficking protein particle complex 4 (TRAPPC4), mRNA NM_016146 2 
Homo sapiens CD59 antigen p18-20 (antigen identified by 
monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) 
(CD59), mRNA 
NM_000611 2 
Human DNA sequence from clone RP11-487F23 on chromosome 
6, complete sequence 
AL355305 2 
Ubiquitin specific protease 16 (USP16), mRNA NM_006447 2 
Hypothetical protein LOC283050 (LOC283050), mRNA XM_210872 2 
Homo sapiens BAC clone RP11-278G12 from 2, complete 
sequence 
AC006369 2 
Fibronectin 1 (FN1), transcript variant 1, mRNA NM_002026 1 
Thioredoxin interacting protein (TXNIP), mRNA NM_006472 1 
Pituitary tumor-transforming 1 interacting protein (PTTG1IP), 
mRNA 
NM_004339 1 
MLL/AF4 fusion protein mRNA, partial cds AF487905 1 
Autophagy Apg3p/Aut1p-like (APG3), mRNA NM_022488 1 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, 
complete cds 
AF261085 1 
Arsenite-resistant protein ASR2 (ASR2) mRNA, complete cds AF248955 1 
Homo sapiens cDNA FLJ26552 fis, clone LNF01613, highly similar 
to Actin,  cytoplasmic 1 
AK130062 1 
Deoxycytidine kinase (DCK), mRNA NM_000788 1 
Zinc finger DAZ interacting protein 1 (DZIP1), mRNA NM_014934 1 
Homo sapiens cDNA: FLJ23493 fis, clone LNG01831, highly 
similar to HSU66589 Human ribosomal protein L5 pseudogene 
AK027146 1 
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mRNA 
Voltage-dependent anion channel 3 (VDAC3), mRNA NM_005662 1 
Protein tyrosine kinase t-Ror1 (Ror1) mRNA, complete cds HSU38894 1 
Phosphatase and tensin homolog (mutated in multiple advanced 
cancers 1) (PTEN), mRNA 
NM_000314 1 
p53 target zinc finger protein (WIG1), mRNA NM_022470 1 
Ribosomal protein S7 (RPS7), mRNA NM_001011 1 
Multidrug resistance-associated protein (ABCC4) mRNA, 
complete cds 
AY081219 1 
ATP synthase, H+ transporting, mitochondrial F1 complex, O 
subunit (oligomycin sensitivity conferring protein) (ATP50), 
mRNA  
NM_001697 1 
Methionyl-tRNA formyltransferase, mitochondrial (MtFMT), 
mRNA 
NM_139242 1 
Splicing factor 3b, subunit 1, 155kDa (SF3B1), mRNA NM_012433 1 
Transmembrane 7 superfamily member 2 (TM7SF2), mRNA NM_003273 1 
Homo sapiens homolog of yeast EME1 endonuclease (FLJ31364), 
mRNA 
NM_152463 1 
Heat shock 90kDa protein 1, alpha (HSPCA), mRNA NM_005348 1 
WD repeat and SOCS box containing protein 2 (WSB2), mRNA NM_018639 1 
Homo sapiens KIAA0100 gene product (KIAA0100), mRNA XM_300673 1 
Isoleucine-tRNA synthetase (IARS), transcript variant long, 
mRNA 
NM_013417 1 
Testis expressed gene 261 (TEX261), mRNA NM_144582 1 
Ribosomal protein L15 (RPL15), mRNA NM_002948 1 
Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) (TGM2), mRNA 
NM_004613 1 
Homo sapiens 12 BAC RP11-968A15 (Roswell Park Cancer 
Institute Human BAC Library) complete sequence 
AC078778 1 
Homo sapiens cDNA: FLJ22147 fis, clone HEP22163, highly 
similar to AF113020 Homo sapiens clone FLB9138 mRNA 
sequence 
AK025800 1 
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Identity of differentially expressed clones NCBI 
accession no. 
Number of 
hits 
Interleukin 8 (IL8), mRNA NM_000584 2 
Sarcolemmal associated protein 1 mRNA,complete cds, 
alternatively spliced 
AF304450 1 
Mixed lineage kinase-related kinase MRK-beta mRNA, complete 
cds 
AF480462 1 
Tumor rejection antigen (gp96) 1 (TRA1), mRNA NM_003299 1 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, beta polypeptide (YWHAB), transcript variant 
1,mRNA 
NM_003404 1 
NCK-associated protein 1 (NCKAP1), mRNA NM_205842 1 
Fucosidase, alpha-L-2, plasma (FUCA2), mRNA NM_032020 1 
Lipopolysaccharide-induced TNF-alpha factor (LITAF), mRNA NM_004862 1 
Homo sapiens mRNA; cDNA DKFZp686H19148 (from clone 
DKFZp686H19148)  
BX648835 1 
Human DNA sequence from clone RP4-753C8 on chromosome 
1p31.3-32.3, complete sequence  
AL139255 1 
BAC clone RP11-173C1 from 2, complete sequence AC019171 1 
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Identity of differentially expressed clones NCBI 
accession no. 
Number of 
hits 
Homo sapiens cDNA FLJ33114 fis, clone TRACH2001289, 
weakly similar to SEX-LETHAL PROTEIN HOMOLOG 
AK057676 8 
Homo sapiens seven in absentia homolog 2 (Drosophila) 
(SIAH2), mRNA 
NM_005067 4 
WEE1 homolog (S. pombe) (WEE1), mRNA NM_003390 4 
Replication protein A1, 70kDa (RPA1), mRNA NM_002945 3 
ATPase, Na+/K+ transporting, beta 1 
polypeptide(ATP1B1),mRNA 
NM_001677 3 
Homo sapiens REV3-like, catalytic subunit of DNA polymerase 
zeta (yeast) (REV3L), mRNA 
NM_002912 2 
Transmembrane 4 superfamily member 10 (TM4SF10), mRNA NM_031442 2 
KIAA1983 protein (FLJ30681), mRNA NM_133459 2 
Angiopoietin-like 2 (ANGPTL2), mRNA NM_012098 2 
Ribosomal protein S24 (RPS24), transcript variant 1, mRNA  NM_033022 2 
Human chromosome 14 DNA sequence BAC R-404P21 of 
library RPCI-11 from chromosome 14 of Homo sapiens 
(Human), complete sequence 
AL355102 2 
Enolase 1, (ENO1), mRNA NM_001428 2 
KIAA1199 protein (KIAA1199), mRNA NM_018689 2 
Kinesin 2 60/70kDa (KNS2), mRNA NM_182923 2 
X-box binding protein 1 (XBP1), mRNA NM_005080 2 
Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
(ITGA5), mRNA 
NM_002205 2 
ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d, 
isoform 1 (ATP6V0D1), mRNA 
NM_004691 2 
N-acylsphingosine amidohydrolase (acid ceramidase) 1, 
transcript variant 1, mRNA 
BC016481 1 
Telomeric repeat binding factor 2, interacting protein 
(TERF2IP), mRNA 
NM_018975 1 
Mixed lineage kinase-related kinase MRK-beta mRNA, complete 
cds 
AF480462 1 
Homo sapiens dishevelled, dsh homolog 3 (Drosophila) (DVL3), 
mRNA 
NM_004423 1 
WD repeat domain 1 (WDR1), mRNA NM_005112 1 
Zinc finger protein 313 (ZNF313), mRNA NM_018683 1 
Coatomer protein complex, subunit beta (COPB), mRNA NM_016451 1 
RNA binding motif protein 24 (RBM24), mRNA NM_153020 1 
Reticulon 4 (RTN4), transcript variant 3, mRNA NM_007008 1 
Calumenin (CALU), mRNA NM_001219 1 
Homo sapiens CAP, adenylate cyclase-associated protein 1 
(yeast) (CAP1), mRNA 
NM_006367 1 
RAB1A, member RAS oncogene family (RAB1A), mRNA NM_004161 1 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit c (subunit 9) isoform 3 (ATP5G3), mRNA 
NM_001689 1 
ATP-binding cassette transporter C4 (ABCC4) mRNA, complete 
cds 
AY207008 1 
Pleckstrin homology domain containing, family M (with RUN 
domain) member 2, mRNA (cDNA clone MGC:87637 
IMAGE:5263629), complete cds 
BC068599 1 
Ribosomal protein L5 (RPL5), mRNA NM_000969 1 
SPARC related modular calcium binding 2 (SMOC2), mRNA NM_022138 1 
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Cyclin I (CCNI) gene, complete cds AY207372 1 
Homo sapiens mRNA; cDNA DKFZp586J021 (from clone 
DKFZp586J021) 
AL110197 1 
Homo sapiens BAC clone RP11-358D17 from 4, complete 
sequence 
AC096745 1 
Homo sapiens chromosome 19 clone CTD-3026N16, complete 
sequence 
AC008755 1 
HEG homolog (HEG), mRNA XM_087386 1 
Human chromosome 14 DNA sequence BAC R-123M6 of library 
RPCI-11 from chromosome 14 of Homo sapiens (Human), 
complete sequence 
AL117190 1 
Human DNA sequence from clone RP11-1M19 on chromosome 
9q34.11-34.3, complete sequence 
AL356862 1 
Homo sapiens cDNA FLJ42206 fis, clone THYMU2035735, 
highly similar to Oryctolagus cuniculus sarcolemmal associated 
protein-3 mRNA 
AK124200 1 
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Identity of differentially expressed genes Unigene 
no. 
Signal 
log 
ratio 
Genes upregulated in CD CLPF compared to CLPF from healthy areas of control patients 
1 immunoglobulin superfamily, member 4 Hs.70337 3.8 
2 fatty acid binding protein 5 (psoriasis-associated) Hs.408061 3.0 
3 brain expressed, X-linked 1 Hs.334370 2.3 
4 Ras-induced senescence 1 Hs.35861 2.1 
 immunoglobulin superfamily, member 4 Hs.70337 1.9 
5 caveolin 1, caveolae protein, 22kDa Hs.74034 1.7 
6 HIV-1 rev binding protein 2 Hs.154762 1.7 
7 metallothionein 1E (functional) Hs.433205 1.6 
8 matrix metalloproteinase 1 (interstitial collagenase) Hs.83169 1.5 
9 sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 
5A 
Hs.27621 1.5 
10 likely ortholog of mouse WD-40-repeat-containing protein with a SOCS 
box 2 
Hs.136644 1.3 
 caveolin 1, caveolae protein, 22kDa Hs.74034 1.2 
11 likely ortholog of mouse RNA polymerase 1-3 (16 kDa subunit) Hs.106127 1.2 
Genes upregulated in CLPF from healthy areas of control patients compared to CD CLPF 
1 Rho family guanine-nucleotide exchange factor Hs.126565 -5.2 
2 collagen, type XIV, alpha 1 (undulin) Hs.403836 -4.5 
3 Homo sapiens cDNA FLJ20286 fis, clone HEP04358. Hs.434483 -3.5 
4 alcohol dehydrogenase IB (class I), beta polypeptide Hs.4 -3.3 
5 chemokine (C-C motif) ligand 11 Hs.54460 -3.2 
6 Homo sapiens cDNA FLJ25677 fis, clone TST04054. Hs.348762 -2.8 
7 DVS27-related protein Hs.348390 -2.7 
8 multimerin Hs.268107 -2.7 
9 myelin basic protein Hs.69547 -2.6 
10 premature ovarian failure 1B Hs.267038 -2.6 
11 spectrin, alpha, erythrocytic 1 (elliptocytosis 2) Hs.1985 -2.6 
12 Homo sapiens PRO2259 mRNA, complete cds Hs.419083 -2.4 
13 prostaglandin D2 synthase 21kDa (brain) Hs.430637 -2.0 
 prostaglandin D2 synthase 21kDa (brain) Hs.430637 -2.0 
14 cathepsin S Hs.181301 -1.9 
15 coagulation factor IX (plasma thromboplastic component, Christmas 
disease, hemophilia B) 
Hs.1330 -1.9 
16 chloride intracellular channel 3 Hs.64746 -1.8 
17 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator Hs.247043 -1.7 
18 LR8 protein Hs.190161 -1.7 
19 glycoprotein A repetitions predominant Hs.151641 -1.5 
20 glycoprotein (transmembrane) nmb Hs.82226 -1.3 
 prostaglandin D2 synthase 21kDa (brain) Hs.430637 -1.3 
21 adipose differentiation-related protein Hs.3416 -1.2 
22 insulin-like growth factor binding protein 6 Hs.274313 -1.1 
23 gamma-aminobutyric acid (GABA) receptor, rho 1 Hs.1438 -1.0 
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Identity of differentially expressed genes Unigene 
no. 
Signal 
log 
ratio 
Genes upregulated in CLPF from strictures of patients with CD compared to CLPF from healthy areas of 
control patients 
1 hypothetical protein FLJ14146 Hs.103395 4.5 
2 neuroligin Hs.21107 4.5 
3 chemokine (C-X-C motif) ligand 14 Hs.24395 4.0 
4 CD14 antigen Hs.75627 3.1 
5 collectin sub-family member 12 Hs.29423 3.0 
6 immunoglobulin superfamily, member 4 Hs.70337 3.0 
7 membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, 
CALLA, CD10) 
Hs.1298 3.0 
 membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, 
CALLA, CD10) 
Hs.1298 2.6 
8 wingless-type MMTV integration site family, member 5A Hs.152213 2.5 
9 ankyrin-like with transmembrane domains 1 Hs.137674 2.2 
10 solute carrier family 12 (potassium/chloride transporters), member 8 Hs.36793 2.2 
11 chemokine (C-X-C motif) ligand 2 Hs.75765 2.1 
12 interleukin 8 Hs.624 2.1 
13 ribosomal protein S11 Hs.182740 2.1 
14 serum-inducible kinase Hs.3838 2.1 
15 a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 1 
Hs.8230 2.0 
16 brain expressed, X-linked 1 Hs.334370 2.0 
17 interleukin 6 (interferon, beta 2) Hs.93913 2.0 
 wingless-type MMTV integration site family, member 5A Hs.152213 1.9 
18 chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 1.9 
 chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 1.9 
19 laminin, alpha 3 Hs.83450 1.9 
20 M-phase phosphoprotein 6 Hs.152720 1.8 
21 NAD(P)H dehydrogenase, quinone 1 Hs.406515 1.8 
22 putative transmembrane protein Hs.78776 1.8 
23 Homo sapiens cDNA FLJ36416 fis, clone THYMU2011053. Hs.184697 1.7 
24 cathepsin B Hs.297939 1.7 
 cathepsin B Hs.297939 1.7 
25 superoxide dismutase 2, mitochondrial Hs.372783 1.7 
 cathepsin B Hs.297939 1.6 
 cathepsin B Hs.297939 1.6 
26 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, 
convertase) 
Hs.2490 1.6 
27 CGI-111 protein Hs.11085 1.6 
28 hypothetical protein PRO1843 Hs.283330 1.6 
29 latexin protein Hs.109276 1.6 
30 N-myc downstream regulated gene 1 Hs.75789 1.6 
31 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-
sialyltransferase; GM3 synthase) 
Hs.225939 1.6 
32 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Hs.11899 1.5 
33 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Hs.139336 1.5 
34 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs.44926 1.5 
35 phosphoribosyl pyrophosphate synthetase 2 Hs.2910 1.5 
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36 plasminogen activator, urokinase Hs.77274 1.5 
37 Rho-specific guanine nucleotide exchange factor p114 Hs.6150 1.5 
38 sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 
5A 
Hs.27621 1.5 
39 nucleoredoxin Hs.374534 1.4 
40 stanniocalcin 2 Hs.155223 1.4 
41 bradykinin receptor B2 Hs.250882 1.3 
42 flavohemoprotein b5+b5R Hs.5741 1.3 
43 Homo sapiens thioredoxin delta 3 (TXN delta 3) mRNA, partial cds Hs.395309 1.3 
44 insulin induced gene 1 Hs.56205 1.3 
45 KIAA0241 protein Hs.150275 1.3 
46 likely ortholog of mouse RNA polymerase 1-3 (16 kDa subunit) Hs.106127 1.3 
47 vascular endothelial growth factor Hs.73793 1.3 
 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs.44926 1.2 
 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs.44926 1.2 
48 SH3-domain binding protein 4 Hs.17667 1.2 
49 hypothetical protein YR-29 Hs.8170 1.2 
50 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) Hs.227280 1.2 
51 potassium inwardly-rectifying channel, subfamily J, member 2 Hs.1547 1.2 
52 sulfide quinone reductase-like (yeast) Hs.8185 1.2 
53 transketolase (Wernicke-Korsakoff syndrome) Hs.89643 1.2 
Genes upregulated in CLPF from healthy areas of control patients compared to CLPF from strictures of 
patients with CD 
1 Rho family guanine-nucleotide exchange factor Hs.126565 -4.5 
2 matrix Gla protein Hs.365706 -4.3 
3 keratin 7 Hs.23881 -3.9 
4 Homo sapiens cDNA FLJ20286 fis, clone HEP04358. Hs.434483 -3.4 
5 CD36 antigen (collagen type I receptor, thrombospondin receptor) Hs.75613 -3.2 
6 chemokine (C-C motif) ligand 11 Hs.54460 -3.2 
7 asporin (LRR class 1) Hs.10760 -3.0 
8 cytokine receptor-like factor 1 Hs.114948 -3.0 
9 paternally expressed 3 Hs.139033 -3.0 
10 DVS27-related protein Hs.348390 -2.9 
11 integrin, alpha 7 Hs.74369 -2.9 
12 Microfibril-associated glycoprotein-2 Hs.300946 -2.8 
13 spectrin, alpha, erythrocytic 1 (elliptocytosis 2) Hs.1985 -2.8 
 paternally expressed 3 Hs.139033 -2.8 
 CD36 antigen (collagen type I receptor, thrombospondin receptor) Hs.75613 -2.8 
14 prostaglandin I2 (prostacyclin) synthase Hs.302085 -2.6 
15 a disintegrin and metalloproteinase domain 12 (meltrin alpha) Hs.8850 -2.5 
16 collagen, type XIV, alpha 1 (undulin) Hs.403836 -2.4 
17 RAB14, member RAS oncogene family Hs.5807 -2.4 
18 alcohol dehydrogenase IB (class I), beta polypeptide Hs.4 -2.3 
19 cadherin 2, type 1, N-cadherin (neuronal) Hs.161 -2.3 
20 desmoplakin (DPI, DPII) Hs.349499 -2.3 
21 EGF-containing fibulin-like extracellular matrix protein 1 Hs.76224 -2.2 
22 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator Hs.247043 -2.2 
23 chondroitin sulfate proteoglycan 2 (versican) Hs.81800 -2.0 
24 Homo sapiens PRO2259 mRNA, complete cds Hs.419083 -2.0 
 EGF-containing fibulin-like extracellular matrix protein 1 Hs.76224 -2.0 
 alcohol dehydrogenase IB (class I), beta polypeptide Hs.4 -2.0 
25 collagen, type XV, alpha 1 Hs.83164 -1.8 
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26 insulin-like growth factor binding protein 3 Hs.77326 -1.8 
27 selenoprotein P, plasma, 1 Hs.275775 -1.8 
28 collagen, type I, alpha 1 Hs.172928 -1.7 
29 cylindromatosis (turban tumor syndrome) Hs.18827 -1.6 
30 Down syndrome critical region gene 1 Hs.184222 -1.6 
31 hypothetical protein FLJ32389 Hs.351558 -1.6 
 chondroitin sulfate proteoglycan 2 (versican) Hs.81800 -1.5 
32 Homo sapiens cDNA: FLJ20933 fis, clone ADSE01388. Hs.296757 -1.4 
33 integrin, beta-like 1 (with EGF-like repeat domains) Hs.82582 -1.4 
 chondroitin sulfate proteoglycan 2 (versican) Hs.81800 -1.4 
34 cytochrome P450, family 2, subfamily C, polypeptide 9 Hs.167529 -1.3 
35 alcohol dehydrogenase 1A (class I), alpha polypeptide Hs.73843 -1.3 
36 biglycan Hs.821 -1.3 
37 glycoprotein A repetitions predominant Hs.151641 -1.3 
38 mesoderm specific transcript homolog (mouse) Hs.79284 -1.3 
39 actin, alpha, cardiac muscle Hs.118127 -1.2 
40 aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-
reductase) 
Hs.201667 -1.2 
41 calponin 1, basic, smooth muscle Hs.21223 -1.2 
42 dapper homolog 1, antagonist of beta-catenin (xenopus) Hs.48950 -1.2 
43 docking protein 5 Hs.127751 -1.2 
44 Notch homolog 3 (Drosophila) Hs.8546 -1.2 
45 pregnancy specific beta-1-glycoprotein 2 Hs.321450 -1.2 
46 butyrylcholinesterase Hs.1327 -1.1 
47 gamma-aminobutyric acid (GABA) receptor, rho 1 Hs.1438 -1.1 
48 zinc finger protein 36, C3H type-like 2 Hs.78909 -1.1 
 cytochrome P450, family 2, subfamily C, polypeptide 9 Hs.167529 -1.1 
 insulin-like growth factor binding protein 3 Hs.77326 -1.1 
 
Table 8 (additional material)  
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Identity of differentially expressed genes Unigene 
no. 
Signal 
log 
ratio 
Genes upregulated in CLPF from CD compared to strictures from the same patient 
1 keratin 7 Hs.23881 3.7 
2 integrin, alpha 7 Hs.74369 3.4 
3 butyrylcholinesterase Hs.1327 2.6 
4 fatty acid binding protein 5 (psoriasis-associated) Hs.408061 2.6 
5 cadherin 2, type 1, N-cadherin (neuronal) Hs.161 2.3 
6 mesoderm specific transcript homolog (mouse) Hs.79284 2.1 
7 EGF-containing fibulin-like extracellular matrix protein 1 Hs.76224 2.0 
 EGF-containing fibulin-like extracellular matrix protein 1 Hs.76224 1.8 
8 docking protein 5 Hs.127751 1.8 
9 FK506 binding protein 11, 19 kDa Hs.24048 1.5 
10 insulin-like growth factor binding protein 3 Hs.77326 1.5 
 insulin-like growth factor binding protein 3 Hs.77326 1.1 
11 selenoprotein P, plasma, 1 Hs.275775 1.5 
12 37 kDa leucine-rich repeat (LRR) protein Hs.155545 1.3 
13 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) Hs.237356 1.3 
14 collagen, type IV, alpha 1 Hs.119129 1.3 
15 HIV-1 rev binding protein 2 Hs.154762 1.3 
16 serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), 
member 2 
Hs.9930 1.0 
Genes upregulated in CLPF from strictures of patients with CD compared to CD CLPF from the same 
patient 
1 hypothetical protein FLJ14146 Hs.103395 -4.8 
2 CD24 antigen (small cell lung carcinoma cluster 4 antigen) Hs.375108 -3.5 
3 complement component 3 Hs.284394 -3.5 
4 plexin C1 Hs.286229 -3.5 
5 chemokine (C-X-C motif) ligand 14 Hs.24395 -3.4 
6 G protein-coupled receptor, family C, group 5, member B Hs.242407 -3.4 
7 hypothetical protein FLJ20151 Hs.279916 -3.3 
8 prostaglandin D2 synthase 21kDa (brain) Hs.430637 -3.3 
9 Homo sapiens cDNA FLJ36416 fis, clone THYMU2011053. Hs.184697 -3.2 
 prostaglandin D2 synthase 21kDa (brain) Hs.430637 -3.2 
10 CD14 antigen Hs.75627 -2.9 
11 chemokine (C-X-C motif) ligand 2 Hs.75765 -2.9 
12 somatostatin Hs.12409 -2.9 
13 LR8 protein Hs.190161 -2.7 
14 periplakin Hs.74304 -2.7 
 CD24 antigen (small cell lung carcinoma cluster 4 antigen) Hs.375108 -2.7 
15 carbonic anhydrase XII Hs.5338 -2.6 
16 vascular cell adhesion molecule 1 Hs.109225 -2.6 
17 ankyrin-like with transmembrane domains 1 Hs.137674 -2.5 
18 Arg/Abl-interacting protein ArgBP2 Hs.379795 -2.5 
19 chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 -2.5 
20 kynureninase (L-kynurenine hydrolase) Hs.169139 -2.5 
21 retinoic acid receptor responder (tazarotene induced) 2 Hs.37682 -2.5 
22 hepatocellular carcinoma-associated antigen 112 Hs.12126 -2.4 
23 bradykinin receptor B2 Hs.250882 -2.3 
 chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 -2.3 
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 hypothetical protein FLJ20151 Hs.279916 -2.3 
 prostaglandin D2 synthase 21kDa (brain) Hs.430637 -2.3 
24 adaptor-related protein complex 1, gamma 1 subunit Hs.5344 -2.2 
25 BCL2-related protein A1 Hs.227817 -2.2 
26 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity) Hs.789 -2.2 
27 Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone 
DKFZp586B0220) 
Hs.170056 -2.2 
28 membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, 
CALLA, CD10) 
Hs.1298 -2.2 
29 potassium inwardly-rectifying channel, subfamily J, member 2 Hs.1547 -2.2 
30 wingless-type MMTV integration site family member 2 Hs.89791 -2.2 
31 growth arrest-specific 1 Hs.65029 -2.1 
 membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, 
CALLA, CD10) 
Hs.1298 -2.1 
32 chemokine (C-X-C motif) ligand 5 Hs.89714 -2.0 
33 Ellis van Creveld syndrome Hs.274446 -2.0 
34 glycoprotein (transmembrane) nmb Hs.82226 -2.0 
35 Rag D protein Hs.238679 -2.0 
36 G protein-coupled receptor kinase 5 Hs.211569 -1.9 
37 solute carrier family 12 (potassium/chloride transporters), member 8 Hs.36793 -1.9 
38 molybdenum cofactor sulfurase Hs.157986 -1.8 
39 serine (or cysteine) proteinase inhibitor, clade F (alpha-2 antiplasmin, 
pigment epithelium derived factor), member 1 
Hs.173594 -1.8 
40 adipose differentiation-related protein Hs.3416 -1.7 
41 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs.44926 -1.7 
 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs.44926 -1.7 
42 putative transmembrane protein Hs.78776 -1.7 
43 synaptosomal-associated protein, 25kDa Hs.84389 -1.7 
44 hypothetical protein DKFZp434L142 Hs.323583 -1.6 
45 spondin 2, extracellular matrix protein Hs.288126 -1.6 
 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs.44926 -1.6 
 G protein-coupled receptor, family C, group 5, member B Hs.242407 -1.6 
46 C-type (calcium dependent, carbohydrate-recognition domain) lectin, 
superfamily member 2 (activation-induced) 
Hs.85201 -1.5 
47 guanine nucleotide exchange factor for Rap1 Hs.80620 -1.5 
48 myelin basic protein Hs.69547 -1.5 
 carbonic anhydrase XII Hs.5338 -1.5 
49 endothelial PAS domain protein 1 Hs.374409 -1.4 
50 guanine nucleotide binding protein (G protein), gamma 11 Hs.83381 -1.4 
51 insulin induced gene 1 Hs.56205 -1.4 
52 insulin receptor substrate 2 Hs.143648 -1.4 
53 lymphocyte antigen 96 Hs.69328 -1.4 
54 prostaglandin E synthase Hs.146688 -1.4 
55 CGI-111 protein Hs.11085 -1.3 
56 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-
sialyltransferase; GM3 synthase) 
Hs.225939 -1.3 
 prostaglandin E synthase Hs.146688 -1.3 
57 cathepsin B Hs.297939 -1.1 
58 KIAA0241 protein Hs.150275 -1.1 
59 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, 
convertase) 
Hs.2490 -1.0 
60 Rho-specific guanine nucleotide exchange factor p114 Hs.6150 -1.0 
 cathepsin B Hs.297939 -1.0 
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Identity of differentially expressed genes Unigene no. 
  
1.) Genes downregulated in CLPF from control patients 
compared to both CLPF from CD and CLPF from strictures of patients with CD 
Down syndrome critical region gene 1 (DSCR1), mRNA NM_004414 
Translin (TSN), mRNA NM_004622 
Homo sapiens mitochondrial genome V00662 
Similar to tubulin tyrosine ligase, clone IMAGE:3865811, mRNA BC036331 
Actin, gamma 1 (ACTG1), mRNA NM_001614 
Cathepsin K (pycnodysostosis) (CTSK), mRNA NM_000396 
Amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) 
(APP), mRNA 
NM_000484 
Humanin (HN1) mRNA, complete cds AY029066 
  
2.) Gene upregulated in CLPF from CD 
compared to both CLPF from control patients and CLPF from strictures 
Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) (ITGA5), mRNA NM_002205 
  
3.) Genes upregulated in CLPF from control patients 
compared to both CLPF from CD and CLPF from strictures of patients with CD 
Rho family guanine-nucleotide exchange factor Hs.126565 
chemokine (C-C motif) ligand 11 Hs.54460 
DVS27-related protein Hs.348390 
spectrin, alpha, erythrocytic 1 (elliptocytosis 2) Hs.1985 
collagen, type XIV, alpha 1 (undulin) Hs.403836 
alcohol dehydrogenase IB (class I), beta polypeptide Hs.4 
type 1 tumor necrosis factor receptor shedding aminopeptidase regulator Hs.247043 
glycoprotein A repetitions predominant Hs.151641 
gamma-aminobutyric acid (GABA) receptor, rho 1 Hs.1438 
  
4.) Genes downregulated in CLPF from control patients 
compared to both CLPF from CD and CLPF from strictures of patients with CD 
likely ortholog of mouse RNA polymerase 1-3 (16 kDa subunit) Hs.106127 
sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A 
Hs.27621 
brain expressed, X-linked 1 Hs.334370 
immunoglobulin superfamily, member 4 Hs.70337 
  
5.) Genes upregulated in CLPF from CD 
compared to both control patients and CLPF from strictures of patients with CD 
HIV-1 rev binding protein 2 Hs.154762 
fatty acid binding protein 5 (psoriasis-associated) Hs.408061 
  
6.) Genes downregulated in CLPF from CD 
compared to both control patients and CLPF from strictures of patients with CD 
prostaglandin D2 synthase 21kDa (brain) Hs.430637 
LR8 protein Hs.190161 
glycoprotein (transmembrane) nmb Hs.82226 
adipose differentiation-related protein Hs.3416 
myelin basic protein Hs.69547 
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7.) Genes upregulated in CLPF from strictures of patients with CD 
compared to both control patients and CLPF from CD 
chemokine (C-X-C motif) ligand 14 Hs.24395 
chemokine (C-X-C motif) ligand 2 Hs.75765 
CD14 antigen Hs.75627 
chitinase 3-like 1 (cartilage glycoprotein-39) Hs.75184 
ankyrin-like with transmembrane domains 1 Hs.137674 
bradykinin receptor B2 Hs.250882 
potassium inwardly-rectifying channel, subfamily J, member 2 Hs.1547 
membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, 
CALLA, CD10) 
Hs.1298 
solute carrier family 12 (potassium/chloride transporters), member 8 Hs.36793 
putative transmembrane protein Hs.78776 
Dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein2) Hs.44926 
insulin induced gene 1 Hs.56205 
sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; 
GM3 synthase) 
Hs.225939 
CGI-111 protein Hs.11085 
cathepsin B Hs.297939 
Rho-specific guanine nucleotide exchange factor p114 Hs.6150 
caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) Hs.2490 
  
8.) Genes downregulated in CLPF from strictures of patients with CD 
compared to both control patients and CLPF from CD 
selenoprotein P, plasma, 1 Hs.275775 
insulin-like growth factor binding protein 3 Hs.77326 
docking protein 5 Hs.127751 
EGF-containing fibulin-like extracellular matrix protein 1 Hs.76224 
mesoderm specific transcript homolog (mouse) Hs.79284 
cadherin 2, type 1, N-cadherin (neuronal) Hs.161 
butyrylcholinesterase Hs.1327 
integrin, alpha 7 Hs.74369 
keratin 7 Hs.23881 
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